The results indicated that the inhibition of CBP/β-catenin suppressed liver fibrosis through the inhibition of HSC activation, which provided novel therapeutic possibilities for treating the liver fibrosis (Figure 3(b)). This evidence concerns the gene CREBBP and Hepatic fibrosis.